Dialysis after heart attack? new study tests shock treatment
NCT ID NCT00780299
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This study tested whether a special type of dialysis (high-permeability hemodialysis) could help people in shock after a cardiac arrest. The treatment aims to remove inflammatory substances from the blood to improve blood pressure and reduce the need for medications. The trial included 38 comatose patients in the ICU and measured how long they needed blood pressure support.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC ARREST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical intensive care unit of Cochin-St Vincent de Paul university Hospital
Paris, 75679, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hemodialysis with high permeability (HDHP)
What this could lead to
If it works, this could offer a new way to manage shock after cardiac arrest, potentially reducing organ failure and early deaths.
What could go wrong
This is a small, completed Phase 3 trial with only 38 participants. The results may not apply to all patients, and the treatment carries risks like bleeding or infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.